戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              CLIA with a standard curve resulted in 36.4% (80/220) po
2 sults were 592 (49.0%; 4Ts score), 73 (6.0%; CLIA), and 50 (4.1%; recommended diagnostic algorithm),
3 Clinical Laboratory Improvement Act of 1988 (CLIA '88), the College of American Pathologists (CAP), a
4 l Laboratory Improvement Amendments of 1988 (CLIA) acceptable blood gas machine equivalent in 74% of
5 l Laboratory Improvement Amendments of 1988 (CLIA) to promote uniform quality and standards among all
6 l Laboratory Improvement Amendments of 1988 (CLIA-waived) have been available commercially in the Uni
7 t of the single-centre, single arm, phase 2, CLIA trial.
8  results were 10 (9.0%; 4Ts score), 5 (4.5%; CLIA), and 15 (13.5%; recommended diagnostic algorithm).
9 nesses that can be identified by employing a CLIA-waived test.
10 e their tumor tested for KRAS mutations in a CLIA-accredited laboratory.
11 mic DNA was tested for the KRAS-variant in a CLIA-certified laboratory.
12  by RNA-seq were independently verified in a CLIA-certified laboratory.
13 or wider availability of therapies, IGP in a CLIA-framework is feasible and valuable in selection/pri
14 is currently utilized by Molecular Vision, a CLIA-certified lab for SARS-CoV-2 diagnosis.
15 perform Clinical Laboratory Improvement Act (CLIA) default QC.
16 ing to Clinical Laboratory Improvements Act (CLIA) guidelines for laboratory-developed tests (LDTs).
17 AT and high sensitivity, the HemosIL AcuStar CLIA seems able to reliably avert empiric plasma exchang
18 linical Laboratories Improvement Amendments (CLIA) and their continuing impact on physician office la
19 linical Laboratories Improvement Amendments (CLIA) and their impact of office practice.
20  Clinical Laboratory Improvement Amendments (CLIA) compliant setting enables a single assay to provid
21  Clinical Laboratory Improvement Amendments (CLIA) criterion for uric acid analysis (+/-17%).
22  Clinical Laboratory Improvement Amendments (CLIA) environment.
23  Clinical Laboratory Improvement Amendments (CLIA) of 1988 regulates the studies that a clinical diag
24  Clinical Laboratory Improvement Amendments (CLIA) validated and has been used prospectively and retr
25  Clinical Laboratory Improvement Amendments (CLIA)- and FDA-approved frameworks.
26  Clinical Laboratory Improvement Amendments (CLIA)-approved CLSI standard agar dilution method and, s
27  Clinical Laboratory Improvement Amendments (CLIA)-waived Flu virus assays.
28  Clinical Laboratory Improvement Amendments (CLIA)-waived setting in comparison to bacterial culture
29  Clinical Laboratory Improvement Amendments (CLIA)-waived, POC PCR influenza assays have been develop
30    Food and Drug Administration-approved and CLIA-waived point-of-care (POC) molecular systems are be
31 ed CCPM Biobank resource within a HIPAA- and CLIA-certified environment.
32 ibody absorption, microhemagglutination, and CLIA was 87.5%, 91.7% and 100%, respectively.
33                   Our sequential approaches (CLIA first and LIA for 15-20% unsolved cases or vice ver
34 star HIT-IgG (chemiluminescent immune assay [CLIA]) and HemosIL HIT-Ab (latex immune-turbidimetric as
35 %CV of 0.29%) in a high throughput automated CLIA laboratory.
36 ugh director responsibilities are defined by CLIA legislation, there is no standardization of job des
37 patients included in a dataset of commercial CLIA-certified laboratory (Caris Life Sciences).
38           However, only this newly developed CLIA test showed high specificity and correlated with th
39                                The developed CLIA allowed the determination of BLC-specific IgE below
40                               While Diasorin CLIA MTTT had a much more rapid, automated, and efficien
41 cificity and intermediate thresholds (ELISA, CLIA), high-dose heparin confirmation step (ELISA), and
42 rderline-negative samples tested with ELISA, CLIA was positive in 42.7% (94/220).
43                                  To evaluate CLIA accuracy, plasma samples from 278 patients undergoi
44                                    Following CLIA guidelines the DKK1 RNAscope chromogenic in situ hy
45 Finally, we discuss the future potential for CLIA-waived POCT-based programs in community pharmacies.
46 he Liaison XL chemiluminescence immunoassay (CLIA) analyzer allows total automation of gamma interfer
47  new sandwich chemiluminescence immunoassay (CLIA) combining an Affimer with a monoclonal antibody (A
48 mosIL AcuStar chemiluminescence immunoassay (CLIA) demonstrated high sensitivity (0.98; 95% confidenc
49 , we report a chemiluminescence immunoassay (CLIA) for multiparametric quantification of specific IgE
50 th commercial chemiluminescence immunoassay (CLIA) method.
51 ation test, a chemiluminescence immunoassay (CLIA), and a Treponema pallidum particle agglutination (
52 wed by a VlsE chemiluminescence immunoassay (CLIA); and (3) a variable major protein-like sequence, e
53 , polyspecific chemiluminescent immunoassay (CLIA) with a high threshold, and immunoglobulin G (IgG)-
54 asorin Liaison chemiluminescent immunoassay (CLIA), to the Zeus enzyme-linked immunoassay (ELISA) MTT
55 g an automated chemiluminescent immunoassay (CLIA).
56 ssays, ELISA; chemiluminescence immunoassay, CLIA; electrochemiluminescence immunoassay, ECLIA; and l
57 s across the country have been incorporating CLIA-waived point-of-care tests (POCT) into disease scre
58                     Implementing the Liaison CLIA for QFT-Plus in low-incidence settings risks falsel
59        This study indicates that Affimer-MAb CLIA can be used to generate a sensitive immunodiagnosti
60 imer with a monoclonal antibody (Affimer-MAb CLIA).
61             Improved sensitivity, molecular, CLIA-waived tests have entered the market in the last 10
62          The specificity was >=97% in anti-N CLIA (100%), anti-S1/S2 CLIA (97.7%), and anti-RBD+LFI (
63              Sensitivity was 84.1% in anti-N CLIA and 66.2% in anti-N ELISA.
64 CLIA, 84.0% in anti-RBD+LFI, 81.0% in anti-N CLIA, 79.2% in anti-RBD ELISA, and 65.6% in anti-N ELISA
65 y was 98.4% in anti-N ECLIA, 98.3% in anti-N CLIA, 98.2% in anti-S1 ELISA, 97.7% in anti-N ELISA, 97.
66               Agreement between the QFT-Plus CLIA and QIAreach with QFT-Plus was excellent (pooled ka
67 luded (44 evaluated the QFT-Plus, 4 QFT-Plus CLIA, 3 QIAreach, 26 TB-IGRA, 10 TB-Feron [1 assessing t
68 s; hereafter index tests: QFT-Plus, QFT-Plus CLIA, QIAreach, Wantai TB-IGRA, Standard E TB-Feron, and
69  Three strategies to mitigate false-positive CLIA results were investigated in 220 samples with borde
70 a viable strategy to mitigate false-positive CLIA results.
71                                 The proposed CLIA assay demonstrated a wide linear range 0.03-600 ng/
72                                    Retesting CLIA false positives (TB1 or TB2 range, 0 to <=1.3 IU/mL
73 SA (92.7%), anti-N ECLIA (91.7%), anti-S1/S2 CLIA (90.3%), anti-RBD+LFI (87.9%), and anti-RBD ELISA (
74  was >=97% in anti-N CLIA (100%), anti-S1/S2 CLIA (97.7%), and anti-RBD+LFI (97.9%).
75          Sensitivity was 84.7% in anti-S1/S2 CLIA, 84.0% in anti-RBD+LFI, 81.0% in anti-N CLIA, 79.2%
76 , 97.7% in anti-N ELISA, 97.6% in anti-S1/S2 CLIA, 97.2% in anti-RBD ELISA, and 96.1% in anti-RBD+LFI
77 omics Network sequencing centers and the six CLIA-accredited laboratories and one research laboratory
78 reshold, and immunoglobulin G (IgG)-specific CLIA with low threshold.
79 ts with high thresholds (ELISA; IgG-specific CLIA), combination of IgG specificity and intermediate t
80                                          The CLIA and TP-PA results were 100% concordant.
81                                          The CLIA had positive and negative percent agreement levels
82 etoclax added to intensive chemotherapy (the CLIA regimen [cladribine, high-dose cytarabine, idarubic
83 he first 2,000 patient samples tested in the CLIA laboratory showed that more than 85% of results wer
84 he diagnostic accuracy of the 4Ts score, the CLIA, and the recommended algorithm serially combining b
85 e first full year of compulsory PT under the CLIA regulations based on the type of testing facility p
86 ration as a component of compliance with the CLIA regulations were obtained.
87 urements across the range of values with the CLIA than with the ELISA.
88 and 128 positives) and subsequently with the CLIA.
89 ns for WGS applications in PHLs according to CLIA guidelines, (ii) the development of quality assuran
90                          Venetoclax added to CLIA was safe and active in patients with newly diagnose
91                               Median time to CLIA-validated results was 116 days with CLIA-validation
92                                      The two CLIA-accredited Electronic Medical Record and Genomics N
93 fractory cancer patients was conducted using CLIA-compliant IGP.
94 rols from Ghana and the United States, using CLIA-certified mass spectrometry-based assays.
95 ajor protein-like sequence, expressed (VlsE) CLIA followed by a C6 EIA.
96       Caris Assure for therapy selection was CLIA validated using 1,910 samples.
97 on-EUA version of the IVD in accordance with CLIA regulations.
98  to CLIA-validated results was 116 days with CLIA-validation of targets achieved in 21/22 patients.
99 based scientific wellness company, each with CLIA-certified whole-genome sequencing data.
100                               Retesting with CLIA reduced the false-positive rate by 10.4% (8/77).
101 h during induction in a patient treated with CLIA-venetoclax plus a FLT3 inhibitor.

 
Page Top